Lionbridge Wins Bronze Stevie® Award for Branded Content Campaign of the Year

September 24, 2024 10:00 PM AEST | By EIN Presswire
 Lionbridge Wins Bronze Stevie® Award for Branded Content Campaign of the Year
Image source: EIN Presswire
WALTHAM, MA, UNITED STATES, September 24, 2024 /EINPresswire.com/ -- Lionbridge, a global leader in translation and localization solutions, was named the winner of a Bronze Stevie® Award for Branded Content Campaign of the Year at the 21st Annual International Business Awards® for its Patient Outcomes Campaign.

The International Business Awards (IBAs) are the world's only international, all-encompassing business awards program. The 2024 IBAs received over 3,600 nominations from organizations in 62 nations and territories. The Stevie® Award for Branded Content Campaign of the Year recognizes work that has used branded content to reach out to audiences to establish meaningful relationships, memorable, engaging experiences, and unique connections with their brands.

Lionbridge designed and executed the Patient Outcomes Campaign to address the challenges faced by customers in recruiting diverse patients, obtaining informed consent, and enhancing patient-centricity in clinical trials. This initiative highlighted Lionbridge’s expertise in clinical trial language solutions, aiming to enhance patient engagement and experience.

The Patient Outcomes Campaign was specifically targeted towards clinical operations, clinical outsourcing management, procurement, regulatory affairs, and translation project managers, with the goal of driving revenue growth.

“This recognition validates our commitment to providing innovative language solutions that address the critical need for clear and effective communication in clinical trials and to include patient perspectives in clinical research,” said Pia Windelov, Vice President of Life Sciences Strategy and Product Marketing at Lionbridge. “By ensuring patients receive culturally appropriate information, we can empower them to make informed decisions about their participation, ultimately contributing to the success of these vital research endeavors.”

Lionbridge Life Sciences has decades of experience providing customized language solutions for clinical trials across all phases, therapeutic areas, indications, and diverse clinical trial participant populations. The team brings deep subject matter expertise, rigorous quality control, and innovative technology.

Discover how Lionbridge can help elevate your clinical trial outcomes here.

About Lionbridge
Lionbridge partners with brands to break barriers and build bridges all over the world. For over 25 years, we have helped companies connect with their global customers and employees by delivering translation and localization solutions in 350+ languages. Through our world-class platform, we orchestrate a network of passionate experts across the globe who partner with brands to create culturally rich experiences. Relentless in our love of linguistics, we use the best of human and machine intelligence to forge understanding that resonates with our customers’ clients. Based in Waltham, Massachusetts, Lionbridge maintains solution centers in 24 countries. Learn more at www.lionbridge.com.

About the Stevie® Awards
Stevie Awards are conferred in nine programs: the Asia-Pacific Stevie Awards, the German Stevie Awards, the Middle East & North Africa Stevie Awards, The American Business Awards®, The International Business Awards®, the Stevie Awards for Great Employers, the Stevie Awards for Women in Business, the Stevie Awards for Technology Excellence, and the Stevie Awards for Sales & Customer Service. Stevie Awards competitions receive more than 12,000 entries each year from organizations in more than 70 nations. Honoring organizations of all types and sizes and the people behind them, the Stevies recognize outstanding performances in the workplace worldwide. Learn more about the Stevie Awards at http://www.StevieAwards.com.

Andie Levine
Lionbridge Technologies, LLC
[email protected]
Visit us on social media:
X
LinkedIn

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.